My name is Crystal Lindell and I’m on opioids — specifically, morphine and hydrocodone
I need these medications on a daily basis to help manage my chronic pain. And by “chronic pain” I mean daily pain so horrible that I literally want to kill myself.
I also have to take hydrocodone pills to help ease something called “breakthrough” pain.
Recently, the U.S. Drug Enforcement Agency decided that the hydrocodone I take should be reclassified to a Schedule II drug.
A lot of people in chronic pain, myself included, are really upset about this. But, if you’re not enduring agonizing pain on a daily basis, I can understand why you might not get what all the fuss is about.
This article speculates on the consequences of the recent rescheduling of hydrocodone products.
the more restrictive policy could also inconvenience millions of Americans and cost taxpayers billions of dollars.
The D.E.A.’s decision represents a “political tug-of-war” between two important public health issues
When the rule takes effect in early October, drugs such as Vicodin
- will only be able to be prescribed for a 90-day period, and
- refills won’t be able to be called in to a pharmacy.
- Patients will have to be seen by a doctor for a new prescription.
- Before this change, patients could receive a 180-day supply.
You may view the new rules in the Federal Register here and read the DEA’s statement here. Scores of advocates, including those of us here at the American Academy of Pain Management, are extremely concerned about the effects that this change will have on those people living with chronic pain who benefit from HCP therapy as part of their treatment plan. Additionally, we are concerned about the potential negative effects that these restrictions will have on healthcare professionals who are diligent in their efforts to alleviate patients’ pain and suffering.
As a reminder, you can view SPPAN’s legislative tracker here. We also recommend familiarizing yourself with your state’s new pain-related legislation by using our End of Session Report, which highlights more than 200 pain-related bills that passed in 2014. If you have any suggestions or comments for improving SPPAN resources, we want to know. Please contact SPPAN Director Amy Goldstein.
Here is an abbreviated Table of Contents for this 101-page document:
- Aim of the Study
- Prevalence of Pain
- Strategic Context
- The People
- Getting a Diagnosis
- Waiting for a Diagnosis
- Support with Diagnosis
- Information, Treatment and Care
- Treatment and Medication
- Information, Advice and Pain Management Support
- How Chronic Pain affects people’s lives
- Impact on Everyday Life
- Acceptance of Pain by Others
- Personal Acceptance of Long-Term Pain
- Living with Pain: Stories
This site has reliable information and the latest research from the NIH on the various complementary medicine approaches to chronic pain.
- What’s the Bottom Line?
- What Is Chronic Pain and Why Is It Important?
- What the Science Says About Safety and Side Effects
- What the Science Says About Complementary Health Approaches for Chronic Pain
- Guidelines for the Treatment of Chronic Pain Conditions
- NCCAM-Funded Research
- If You Are Considering Complementary Health Approaches for Chronic Pain
- Key References
- For More Information
Neuromuscular Features of Ehlers-Danlos Syndrome and Marfan syndrome – expanding the phenotype of inherited connective tissue disorders and investigating the role of the extracellular matrix in muscle.
This 2011 PhD thesis of Nicol Voermans is a collection of NIH research studies detailing muscle problems in EDS. It includes diagnostic criteria and a literature review of neuromuscular involvement in various types of Ehlers-Danlos syndrome. Chapters include:
- Clinical evaluation of Ehlers-Danlos syndrome patients
- Quantitative muscle function measurements of tenascin-X-deficient Ehlers-Danlos syndrome patients and tenascin-XB knockout mice
Sometimes that day in the hospital rushes back to me. I went in to have that beautiful baby girl…
The “doctor” (who I later found was a nurse assistant) jammed the epidural needle into my spine. I’m a tough girl. I was expecting something jammed into my spine. He started the medication and I couldn’t take it – I felt pinching, burning, fire, lightning! I finally screamed and moaned. With the needle still in me, he asked, “Why didn’t you tell me I missed?”
He had just given me Arachnoiditis, aseptic meningitis and chemical meningitis. And in no way acknowledged it.
Curcumin, a component of the traditional Indian spice, turmeric, is highly effective in combating the symptoms of major depressive disorder, according to research published in the Journal of Affective Disorders.
There is now increasing support for the antidepressant effects of curcumin, with a previous study demonstrating BCM-95 curcumin to be as effective as a pharmaceutical antidepressant for the treatment of depression,
According to the study authors, curcumin “influences several biological mechanisms associated with major depression, namely those associated with monoaminergic activity, immune-inflammatory and oxidative and nitrosative stress pathways, hypothalamus-pituitary-adrenal axis activity, and neuroprogression.” BCM-95 said it is critical to note that its version of curcumin is unique in the sense that it is designed for high absorption and includes turmeric essential oil, which is not present in standard curcumin.
In the past year, Sanjay Gupta has made no secret of his support for medical marijuana.
“In terms of making this legal for medicinal purposes — yes, and there are both very pragmatic reasons and more subjective reasons for that,” Gupta said.
Seven-year-old Charlotte Figi, for whom the strain was named, used to suffer from hundreds of seizures a week. She was the first child in Colorado to be legally treated with cannabis since medical marijuana was decriminalized. Charlotte’s recovery has been miraculous, her mother, Paige Figi, told The Huffington Post. “She is getting a re-do of all the years she was robbed by epilepsy,” Paige said.
After 10 years of formal debate and consideration – and 15 years since the idea was first proposed – hydrocodone combination products are being reclassified from the more-permissive Schedule III to the more-restrictive Schedule II category.
It’s a balancing act. But we have enough evidence that placing more restrictions on hydrocodone combination products is in the interest of public safety.
This five-category progressive classification system for controlled substances, Schedule I through V, was established by the U.S. Congress in 1971 with the passage of the Controlled Substances Act (CSA). The CSA governs how prescription drugs with abuse potential are prescribed and distributed.